# Ipamorelin Benefits Reported in Research, From Bone to Body Composition > Ipamorelin Benefits Reported in Research: dose-dependent bone growth in rats, a selective GH pulse, bone-mineral content gains, and steroid-bone rescue — with the human gaps named, every figure cited. What the studies actually credit to ipamorelin — led by the skeletal data — set beside the honest limits of where that evidence stops. ## In plain English The Ipamorelin Benefits Reported in Research fall into two buckets, and it helps to keep them straight. The sturdy ones come from animal studies of bone and growth hormone: in rats, ipamorelin made long bones grow faster in proportion to the dose [4], added bone mineral content over 12 weeks [8], and partly rescued bone weakened by steroids [7]. The softer ones come from what people say they notice — better sleep, faster recovery — which are stories, not studies, and live on [the effects page](/effects). The single most important caveat is this: the strong benefits are all preclinical, measured in rodents, and the one human trial that tested ipamorelin for a real condition did not work [3]. So this page celebrates what the studies genuinely found while being clear about how far it has, and has not, been shown in people. ## The bone benefit, in detail The clearest documented benefit is skeletal. In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms a day for 15 days raised the longitudinal bone-growth rate step by step with the dose — from 42 to 44, 50, and 52 micrometers a day — and did so without changing blood IGF-1 or bone-turnover markers [4]. Over a longer 12-week window, continuous delivery at 0.5 mg/kg per day increased total tibial and vertebral bone mineral content, though the volumetric density was unchanged — meaning the benefit took the form of larger bone dimensions rather than greater density [8]. And in steroid-weakened bone, ipamorelin lifted the periosteal bone-formation rate about four-fold over the steroid alone while improving muscle force [7]. Read together, these are a reproducible, dose-responsive skeletal benefit — entirely in rodents. ## The growth-hormone benefit and its clean profile The benefit that underlies the others is a selective growth-hormone pulse. Ipamorelin releases growth hormone potently while leaving ACTH, cortisol, and prolactin essentially unmoved even at more than 200 times its growth-hormone threshold [1]. That selectivity is itself the benefit researchers highlight: a GH-releasing effect without the adrenal and prolactin stimulation that burden less-selective peptides [1]. In a steroid-suppression model, the growth-hormone response held up and IGF-1 rose, with body weight recovering in combination [13]. The benefit is mechanistically clean — but it is characterized acutely and in animals, and a clean mechanism is not the same as a proven human outcome. ## Body composition and the honest limit Beyond bone, animal and mechanistic work points to body-composition effects: ipamorelin raised fat-pad weight and the fat-signal leptin in both growth-hormone-deficient and normal mice, showing a partly growth-hormone-independent action on adiposity through the ghrelin pathway [10]. The community reads this as a body-recomposition benefit, but the mouse data cut both ways — toward fat gain as much as fat loss — which is why this site files appetite and adiposity under cautions as well [12] [10]. The honest limit on every benefit here is the same: the strong evidence is preclinical, the lone human efficacy trial missed [3], and there is no approved indication [3]. The [ipamorelin benefits](/benefits) worth taking seriously are exactly the ones the studies measured — no more. --- An md-desk reading of the ipamorelin record, led by the rat bone-growth data and kept honest about where the human evidence thins — every figure carried back to its study, no clinic behind the name and nothing dispensed.